Table 2.
Clinical Outcomes
| OPR (n=905) | HPR (n=196) | P Value | |
|---|---|---|---|
| One‐year outcome | |||
| All‐cause death | 37 (4.1) | 12 (6.1) | 0.211 |
| Cardiac death | 24 (2.7) | 10 (5.1) | 0.072 |
| Nonfatal myocardial infarction | 13 (1.4) | 4 (2.1) | 0.529 |
| Stroke | 4 (0.5) | 0 (0) | 0.355 |
| CTO‐vessel repeated PCI | 95 (10.5) | 21 (10.8) | 0.918 |
| CABG | 10 (1.1) | 1 (0.5) | 0.448 |
| MACCE | 146 (16) | 36 (18) | 0.445 |
| Definite/probable stent thrombosis | 5 (1.0) | 2 (2.2) | 0.366 |
| Composite of coronary eventsa | 42 (4.6) | 16 (8.1) | 0.045 |
| Long‐term survival | |||
| Cardiac survival | |||
| 1 y | 97.6±0.5 | 94.9±1.6 | <0.001 |
| 3 y | 95.3±0.8 | 86.2±2.8 | |
| All‐cause death | |||
| 3 y | 86±1.5 | 75±3.7 | 0.001 |
Values are number of events (%) or mean±SE for survival analyses. CABG indicates coronary artery bypass grafting; CTO, chronic total occlusion; HPR, high platelet reactivity; MACCE, major acute cardiovascular and cerebrovascular events; OPR, optimal platelet reactivity; PCI, percutaneous coronary intervention.
a
Composite of cardiac death, nonfatal myocardial infarction, and stent thrombosis.